The US Food and Drug Administration will need to change Eli Lilly and Company’s letter of authorization for bebtelovimab in order for the company to transition its COIVD-19 monoclonal antibody to the commercial market, a prospect other sponsors may need to think about as US government pandemic funding runs low.
The drug’s current authorization says that distribution will be controlled by the US government and directs Lilly to supply the drug to healthcare
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?